Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Astria Therapeutics (ATXS), a biopharmaceutical company developing therapies for allergic and immunologic diseases, has granted stock options to five new employees under its 2022 Inducement Stock Incentive Plan. The options cover 87,450 shares of common stock with an exercise price of $6.10, matching the closing price on March 3, 2025.
The options will vest over four years, with 25% vesting on the first employment anniversary and the remainder vesting monthly over the following 36 months, contingent on continued employment. These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as inducement for new hires.
Astria Therapeutics (ATXS), un'azienda biofarmaceutica che sviluppa terapie per malattie allergiche e immunologiche, ha concesso opzioni su azioni a cinque nuovi dipendenti nell'ambito del suo Piano di Incentivazione Azionaria per il 2022. Le opzioni coprono 87.450 azioni ordinarie con un prezzo di esercizio di $6.10, corrispondente al prezzo di chiusura del 3 marzo 2025.
Le opzioni matureranno in quattro anni, con il 25% che matura al primo anniversario di assunzione e il resto che matura mensilmente nei successivi 36 mesi, a condizione di continuare l'impiego. Questi conferimenti sono stati effettuati in conformità con la Regola di Quotazione Nasdaq 5635(c)(4) come incentivo per le nuove assunzioni.
Astria Therapeutics (ATXS), una empresa biofarmacéutica que desarrolla terapias para enfermedades alérgicas e inmunológicas, ha otorgado opciones sobre acciones a cinco nuevos empleados bajo su Plan de Incentivos de Acciones por Inducción de 2022. Las opciones cubren 87,450 acciones ordinarias con un precio de ejercicio de $6.10, igualando el precio de cierre del 3 de marzo de 2025.
Las opciones se consolidarán durante cuatro años, con el 25% consolidándose en el primer aniversario de empleo y el resto consolidándose mensualmente durante los siguientes 36 meses, sujeto a la continuidad del empleo. Estas concesiones se hicieron de acuerdo con la Regla de Cotización de Nasdaq 5635(c)(4) como incentivo para las nuevas contrataciones.
Astria Therapeutics (ATXS), 알레르기 및 면역 질환 치료제를 개발하는 생명공학 회사가 2022년 유인 주식 인센티브 계획에 따라 다섯 명의 신규 직원에게 주식 옵션을 부여했습니다. 이 옵션은 $6.10의 행사가로 87,450주의 보통주를 포함하고 있으며, 2025년 3월 3일의 종가와 일치합니다.
옵션은 4년에 걸쳐 발생하며, 25%는 첫 해 고용 기념일에 발생하고 나머지는 이후 36개월 동안 매달 발생하며, 계속 고용되는 조건입니다. 이러한 부여는 새로운 채용을 위한 유인책으로 Nasdaq 상장 규칙 5635(c)(4)에 따라 이루어졌습니다.
Astria Therapeutics (ATXS), une entreprise biopharmaceutique développant des thérapies pour les maladies allergiques et immunologiques, a accordé des options d'achat d'actions à cinq nouveaux employés dans le cadre de son Plan d'Incentive d'Actions par Induction de 2022. Les options couvrent 87 450 actions ordinaires à un prix d'exercice de $6.10, correspondant au prix de clôture du 3 mars 2025.
Les options seront acquises sur quatre ans, avec 25% acquises lors du premier anniversaire d'embauche et le reste acquis mensuellement au cours des 36 mois suivants, sous réserve de maintien de l'emploi. Ces attributions ont été faites conformément à la règle de cotation Nasdaq 5635(c)(4) en tant qu'incitation pour les nouvelles recrues.
Astria Therapeutics (ATXS), ein biopharmazeutisches Unternehmen, das Therapien für allergische und immunologische Krankheiten entwickelt, hat fünf neuen Mitarbeitern im Rahmen seines Inducement Stock Incentive Plans 2022 Aktienoptionen gewährt. Die Optionen betreffen 87.450 Stammaktien mit einem Ausübungspreis von $6.10, der dem Schlusskurs vom 3. März 2025 entspricht.
Die Optionen werden über vier Jahre fällig, wobei 25% am ersten Jahrestag der Anstellung fällig werden und der Rest in den folgenden 36 Monaten monatlich fällig wird, abhängig von der Fortsetzung der Anstellung. Diese Zuwendungen wurden gemäß der Nasdaq-Listing-Regel 5635(c)(4) als Anreiz für neue Einstellungen gewährt.
- Employee retention incentive through 4-year vesting schedule
- Successful attraction of new talent with equity compensation
- Potential future dilution from 87,450 new stock options
The options were granted as an inducement material to five employees entering into employment with Astria in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of
About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Our lead program, navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in clinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com, or follow us on Instagram @AstriaTx and on Facebook and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250304130861/en/
Astria Contact:
Investor Relations and Media:
Elizabeth Higgins
investors@astriatx.com
Source: Astria Therapeutics, Inc.
FAQ
How many stock options did Astria Therapeutics (ATXS) grant in March 2025?
What is the exercise price for ATXS stock options granted on March 3, 2025?
What is the vesting schedule for the new ATXS stock options?
How many employees received stock options from ATXS in this grant?
